Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Viatris Inc. (VTRS) trades at a price to free cash flow of 11.5×. Over the past ten years it has ranged from 2.1× (April 2025) to 135× (July 2015); the current reading is higher than 59% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.1× and below the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 7.5× 125.96%
FY2024 3.3× (31.78%)
FY2023 4.9× (9.15%)
FY2022 5.4× (17.11%)
FY2021 6.5× (68.23%)
FY2020 20.4× 180.37%
FY2019 7.3× (39.38%)
FY2018 12.0× (34.66%)
FY2017 18.4× 18.63%
FY2016 15.5× (30.96%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 9.8× 7.77%
Mar 2026 9.1× 20.62%
Dec 2025 7.5× 6.77%
Sep 2025 7.0× 139.68%
42 more quarters

Against its own ten years

Low 2.1× High 135×
Ten-year median 9.2×
Current reading's percentile 59

Price to free cash flow against peers

Company Price to free cash flow
TAK Takeda Pharmaceutical Co. compare 8.4×
HLN Haleon PLC Sponsored ADR compare 10.2×
VTRS Viatris Inc. 11.5×
ZTS Zoetis Inc. compare 14.2×
NBIX Neurocrine Biosciences, Inc. compare 15.7×
UTHR United Therapeutics Corporation compare 20.9×
ELAN Elanco Animal Health Incorporated compare 33.0×
TEVA Teva Pharmaceutical Industries Ltd. compare 34.5×
RDY Dr. Reddy's Laboratories Ltd compare 73.5×
Drug Manufacturers Specialty & Generic industry median 16.1×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on VTRS